Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, No. 507 Zhengmin Road, Shanghai, 200433, China.
BMC Pulm Med. 2024 Oct 17;24(1):519. doi: 10.1186/s12890-024-03313-1.
In small cell lung cancer (SCLC), the pathological N category is identical to it in non-small cell lung cancer (NSCLC) and remains unchanged over a decade. Here we verified the discriminability of number of involved nodal stations (nS) in SCLC and compared its efficacy in predicting survival with currently used pathological nodal (pN) staging.
We retrospectively analyzed the patients who received operations and were pathologically diagnosed as SCLC at Shanghai Pulmonary Hospital between 2009 and 2019. X-tile software was adopted to determine optimal cut-off values for nS groups. Kaplan-Meier method and Cox regression analysis were used to compare survival between different groups. Decision curve analysis (DCA) was employed to evaluate the standardized net benefit.
A total of 369 patients were included. The median number of sampled stations was 6 (range 3-11), and the median number of positive stations was 1 (range 0-7). The optimal cutoff for nS groups was: nS0 (no station involved), nS1-2 (one or two stations involved), and nS ≥ 3 (three or more stations involved). Overall survival (OS) and relapse-free survival (RFS) were statistically different among all adjacent categories within the nS classification (p < 0.001, for both OS and RFS between each two subgroups), but survival curves for subgroups in pN overlapped (OS, p = 0.067; RFS, p = 0.068, pN2 vs. pN1). After adjusting for other confounders, nS was a prognostic indicator for OS and RFS. The DCA revealed that nS had improved predictive capability than pN.
Our cohort study demonstrated that the nS might serve as a superior indicator to predict survival than pN in SCLC and was worth considering in the future definition of the N category.
在小细胞肺癌(SCLC)中,病理 N 分期与非小细胞肺癌(NSCLC)相同,且十年来一直保持不变。在此,我们验证了 SCLC 中受累淋巴结站(nS)数量的可区分性,并比较了其在预测生存方面的有效性与目前使用的病理淋巴结(pN)分期。
我们回顾性分析了 2009 年至 2019 年在上海肺科医院接受手术并经病理诊断为 SCLC 的患者。采用 X-tile 软件确定 nS 分组的最佳截断值。Kaplan-Meier 法和 Cox 回归分析用于比较不同组之间的生存情况。决策曲线分析(DCA)用于评估标准化净获益。
共纳入 369 例患者。取样站中位数为 6 个(范围 3-11 个),阳性站中位数为 1 个(范围 0-7 个)。nS 分组的最佳截断值为:nS0(无站受累)、nS1-2(一个或两个站受累)和 nS≥3(三个或更多站受累)。nS 分类中所有相邻亚组之间的总生存(OS)和无复发生存(RFS)均有统计学差异(OS 和 RFS 中,所有两两亚组之间 p<0.001),但 pN 亚组的生存曲线重叠(OS,p=0.067;RFS,p=0.068,pN2 与 pN1)。调整其他混杂因素后,nS 是 OS 和 RFS 的预后指标。DCA 显示,nS 比 pN 具有更好的预测能力。
本队列研究表明,在 SCLC 中,nS 可能是比 pN 更能预测生存的指标,在未来 N 分期的定义中值得考虑。